DR. ANGEL K. MARKOV, MD
Osteopathic Medicine at State St, Jackson, MS

License number

Mississippi 06746

Personal information

See more information about ANGEL K. MARKOV at radaris.com

Name

Address

Phone

Angel Markov, age 88

5973 Hanging Moss Rd, Jackson, MS 39206

(601) 362-5751

Angel K Markov, age 88

5973 Hanging Moss Rd, Jackson, MS 39206

(601) 362-5119
(601) 362-5751

Angel Markov

2500 State St, Jackson, MS 39216

(601) 984-5630

Professional information

Use Of Fructose-1 6-Diphosphate As An Inotrope Drug After Cardiopulmonary Bypass Surgery

US Patent:

5944020, Aug 31, 1999

Filed:

Oct 3, 1997

Appl. No.:

8/943836

Inventors:

Angel K. Markov - Jackson MS
Paul J. Marangos - Encinitas CA
Anthony W. Fox - Rancho LaCosta CA

Assignee:

Cypros Pharmaceutical Corp. - Carlsbad CA

International Classification:

A61B 1900

US Classification:

128898

Abstract:

When fructose-1,6-diphosphate (FDP) is used as an inotropic drug in patients who have undergone surgery involving cardiopulmonary bypass, it can increase the pumping strength of a struggling heart, without increasing the heartbeat rate. As such, FDP can reduce the dosages of (and in some some cases eliminate the need for) other inotropic drugs such as dobutamine, epinephrin, or amrinone lactate, which have undesired and potentially dangerous side effects, mainly involving increasing the heartbeat rate, which imposes substantial additional stresses on hearts that are struggling to regain strength after cardiopulmonary bypass surgery.

Angel Kroum Markov, Jackson MS

Specialties:

Internal Medicine, Cardiovascular Disease, Cardiology

Work:

University of Mississippi Medical Center
2500 N State St, Jackson, MS 39216

Education:

Katholieke Universiteit Leuven (1972)

Angel K Markov, Jackson MS

Specialties:

Cardiologist

Address:

2500 N State St, Jackson, MS 39216

Treatment Of Sickle Cell Anemia Crises With Fructose-1,6-Diphosphate As An Analgesic Drug

US Patent:

6312707, Nov 6, 2001

Filed:

Jun 12, 2000

Appl. No.:

9/591786

Inventors:

Angel K. Markov - Jackson MS
Anthony W. Fox - Rancho LaCosta CA
Paul J. Marangos - Encinitas CA

Assignee:

Questcor Pharmaceuticals, Inc. - Union City CA

International Classification:

A61F 202

US Classification:

424423

Abstract:

Fructose-1,6-diphosphate (FDP) has been shown, in double-blinded controlled clinical trials on patients with sickle cell anemia, to substantially reduce the pain suffered by such patients during the recurrent ischemic crises that are caused by red blood cell sickling. Tests on patients who have been hospitalized for such crises demonstrated that when they received an intravenous injection of FDP, they reported substantially lower pain levels during their hospital stays than control groups that received identical treatment without any FDP. Apparently, FDP has never previously been used or even tested in human clinical trials, to treat sickle cell anemia. In addition, FDP has never previously been reported to have any analgesic (pain-reducing) activity.

Treatment Of Sickle Cell Anemia Crises With Fructose-1, 6-Diphosphate As An Analgesic Drug

US Patent:

6074658, Jun 13, 2000

Filed:

Oct 3, 1997

Appl. No.:

8/943688

Inventors:

Angel K. Markov - Jackson MS
Anthony W. Fox - Rancho LaCosta CA
Paul J. Marangos - Encinitas CA

Assignee:

Cypros Pharmaceutical Corp. - Carlsbad CA

International Classification:

A61F 202

US Classification:

424423

Abstract:

Treatment Of Asthma With Fructose-1,6-Diphosphate

US Patent:

5858985, Jan 12, 1999

Filed:

Oct 3, 1997

Appl. No.:

8/943438

Inventors:

Angel K. Markov - Jackson MS

International Classification:

A61K 3170, C07H 1104

US Classification:

514 25

Abstract:

Fructose-1,6-diphosphate (FDP), a sugar-phosphate compound, can be useful in treating asthma, when administered as an inhalable drug, either by itself or as a component of a mixed formulation. On a cellular level, inhalable FDP appears to offer at least four beneficial effects for asthma sufferers: (1) it reduces histamine release by activated mast cells; (2) it suppresses production of oxygen free radicals by polymorphonuclear cells; (3) it helps suppress the activation and proliferation of T-lymphocytes; and, (4) it helps reduce the expression of interleukin compounds by T-lymphocytes. All four effects have been measured and shown to occur in animal and/or human tests, and these effects render FDP likely to help reduce and retard the progressive worsening of asthma that occurs in many sufferers. In addition, when tested in inhalable form on humans, FDP was shown to increase bronchial flow rates. All of these effects are beneficial, and can help asthma patients treated with FDP use asthma-control drugs which impose less stress on the user than more potent, aggressive asthma-control drugs.

Use Of Fructose-1,6-Diphosphate For Treating Myocardial Infarction

US Patent:

4546095, Oct 8, 1985

Filed:

Sep 3, 1982

Appl. No.:

6/414551

Inventors:

Angel K. Markov - Jackson MS

International Classification:

A61K 3166, A61K 3170, C12P 1924

US Classification:

514 23

Abstract:

The invention relates to the treatment of heart disorders. Disruption of heart action or occulision of heart artery results in oxygen deprivation and aerobic metabolism ceases. Unless effective treatment is administered acidosis renders anaerobic metabolism inactive and irreversible tissue damage occurs. Fructose-1,6-diphosphate is used as a therapeutic agent for treating mammalian subjects experiencing myocardial infection in order to prevent ischemic tissue from irreversible tissue damage.

Treatment Of Adult Respiratory Distress Syndrome (Ards) Using Fructose Diphosphate (Fdp)

US Patent:

4703040, Oct 27, 1987

Filed:

Oct 8, 1985

Appl. No.:

6/785778

Inventors:

Angel K. Markov - Jackson MS

International Classification:

C07H 1104, A61K 910, A61K 3166

US Classification:

514 23

Abstract:

Fructose-1,6-diphosphate is administered intravenously to a mammalian subject experiencing adult respiratory distress syndrome (ARDS) in an amount sufficient to inhibit pulmonary microvascular damage.